Fenitab 200 Mg (Sorafenib) Tablets

Introduction

Fenitab 200 mg (Sorafenib) represents a breakthrough in targeted cancer therapy, specifically designed for patients battling unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). As a potent kinase inhibitor, Fenitab works by inhibiting multiple cellular pathways responsible for tumor growth, effectively slowing cancer progression and improving patient outcomes.

Key Therapeutic Benefits

Fenitab delivers powerful anti-cancer effects through its innovative mechanism of action:

Tumor Growth Inhibition: Directly targets and inhibits multiple intracellular kinases (CRAF, BRAF and mutant BRAF)
Anti-Angiogenic Properties: Blocks cell surface kinases (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β) responsible for blood vessel formation
Dual-Action Approach: Simultaneously targets cancer cells while disrupting tumor blood supply
Proven Efficacy: Demonstrated inhibition of tumor growth in clinical studies for both HCC and RCC

Primary Indications

Fenitab 200 mg is specifically indicated for:

Hepatocellular Carcinoma (HCC)

For patients diagnosed with unresectable hepatocellular carcinoma – the most common type of primary liver cancer – when surgical removal is not possible. Fenitab provides a crucial treatment option for extending survival and maintaining quality of life.

Renal Cell Carcinoma (RCC)

Recommended for patients with advanced renal cell carcinoma, the most common type of kidney cancer. Fenitab serves as an effective therapeutic intervention when the cancer has progressed beyond early-stage treatment options.

Dosage & Administration Guidelines

The optimal therapeutic regimen for Fenitab includes:

Standard Dosage: 400mg (two tablets) twice daily
Administration Timing: Take without food (at least 1 hour before or 2 hours after meals)
Treatment Duration: Continue until clinical benefit ceases or unacceptable toxicity occurs
Missed Dose Protocol: Skip missed dose and take next dose at regular time; do not double-dose

Dose Adjustment Recommendations

For patients experiencing adverse reactions, dosage adjustments may include:

First Reduction: 400mg once daily
Further Reduction: 400mg every other day
Treatment Interruption: Temporary pauses based on severity of side effects
Personalized Approach: No adjustments required based on age, gender, or body weight

Advanced Pharmacological Profile

Fenitab’s powerful mechanism of action targets multiple cancer pathways:

Multi-Kinase Inhibition: Blocks both intracellular and cell surface kinases
Anti-Proliferative Effects: Decreases cancer cell multiplication
Apoptosis Induction: Promotes programmed cancer cell death
Anti-Angiogenic Activity: Reduces formation of new blood vessels feeding tumors

Clinical Considerations & Management

Healthcare providers should consider these important aspects when prescribing Fenitab:

Potential Interactions

Fenitab may interact with several medications, requiring careful management:

Anticoagulants: Regular monitoring of prothrombin time/INR with warfarin co-administration
Chemotherapy Agents: Potential increases in exposure to docetaxel (36-80%), doxorubicin (21%)
CYP Substrates: Increased exposure to CYP2B6 and CYP2C8 substrates
Enzyme Inducers: Reduced Fenitab effectiveness with rifampicin (37% reduction) and other CYP3A4 inducers
Neomycin: Decreased Fenitab exposure (54% reduction) with oral neomycin co-administration

Contraindications

Fenitab should not be administered in:

Hypersensitivity Cases: Patients with known severe allergic reactions to sorafenib
Combination Therapy: With carboplatin and paclitaxel in squamous cell lung cancer patients

Safety Monitoring Recommendations

Vigilant monitoring is essential for:

Cardiovascular Status: Monitor for cardiac ischemia/infarction
Blood Pressure: Regular assessment for hypertension
Dermatologic Conditions: Early identification of hand-foot skin reactions
Bleeding Risk: Assessment for hemorrhagic complications
Surgical Recovery: Evaluation of wound healing before resuming therapy

Managing Side Effects

Proactive management of adverse reactions enhances treatment adherence:

Hand-Foot Skin Reaction (HFSR)

Tiered approach based on severity:

Grade 1 (Mild): Continue treatment with symptomatic topical therapy
Grade 2 (Moderate): Consider treatment interruption if no improvement within 7 days
Grade 3 (Severe): Interrupt treatment until resolved to Grade 0-1; reduce dosage upon resumption

Other Common Side Effects

Cardiovascular: Implement appropriate monitoring for hypertension and cardiac events
Gastrointestinal: Manage diarrhea with supportive care; discontinue if perforation occurs
Dermatologic: Treat rash with topical therapies; consider dose adjustments for severe reactions

Special Population Considerations

Fenitab dosing may require special attention for:

Renal Impairment: No dose adjustment necessary for any degree of renal dysfunction
Hepatic Impairment: Suitable for Child-Pugh A and B; not studied in Child-Pugh C
Geriatric Patients: No differences in safety or efficacy observed in older populations
Pediatric Use: Safety and effectiveness not established in children

Quality Assurance & Manufacturing

Fenitab 200 mg tablets are manufactured by Eskayef Pharmaceuticals Ltd., a premier Bangladesh pharmaceutical company with over 31 years of excellence in medication production. Each batch undergoes rigorous quality control to ensure optimal therapeutic efficacy and patient safety.

Storage Guidelines

To maintain product integrity:

Store at controlled room temperature below 30°C
Keep in original bottle with desiccant
Protect from excessive heat and moisture

Global Availability

Through Orio Pharma’s dedicated oncology medicine supply network, Fenitab is available with:

Worldwide shipping to healthcare facilities and pharmacies
Expedited delivery within 3-7 working days
Complete tracking and support throughout the ordering process
Comprehensive documentation and quality certificates

Fenitab 200 mg (Sorafenib) represents a significant advancement in targeted cancer therapy, offering hope and extended survival for patients with unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Through its innovative multi-kinase inhibition mechanism, Fenitab addresses critical pathways in cancer progression, providing an essential treatment option in the oncologist’s arsenal against these challenging malignancies.